logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11896574 B1

PDFFull Text
Date of Patent:
Feb. 13, 2024

Filed:

Mar. 01, 2020

Treatment of metabolic disorders in feline animals

Applicant:

Boehringer Ingelheim Vetmedica Gmbh, Ingelheim am Rhein, DE;

Inventors:

Dania Birte Reiche, Bingen am Rhein, DE;

Silke Haag-Diergarten, Frankfurt am Main, DE;

Leah Jeanette Hennings, Kansas City, MO (US);

Saskia Kley, Appenheim, DE;

Anne M. Traas, Saint Joseph, MO (US);

Assignee:
Attorney:

Katrina Bergbauer

Primary Examiner:

Eric Olson

Int. Cl.
CPC ...
A61K 31/351 (2006.01); A61P 3/10 (2006.01); A61K 38/28 (2006.01); A61K 31/7034 (2006.01); C07D 309/10 (2006.01); C07H 7/04 (2006.01); A61K 31/7042 (2006.01); C07D 493/10 (2006.01); C07D 493/08 (2006.01); A61P 3/06 (2006.01); A61P 31/12 (2006.01); A61K 31/357 (2006.01); A61P 9/12 (2006.01); A61K 31/381 (2006.01); A61K 31/7056 (2006.01); C07H 17/02 (2006.01); C07D 335/02 (2006.01); A61K 31/35 (2006.01); A61K 47/22 (2006.01); C07D 333/12 (2006.01); A61P 5/50 (2006.01); A61P 3/04 (2006.01); C07H 17/00 (2006.01); C07H 5/10 (2006.01); A61P 3/00 (2006.01); C07H 15/203 (2006.01); A61P 29/00 (2006.01); C07D 333/56 (2006.01);
U.S. Cl.
CPC ...
A61K 31/351 (2013.01); A61K 31/35 (2013.01); A61K 31/357 (2013.01); A61K 31/381 (2013.01); A61K 31/7034 (2013.01); A61K 31/7042 (2013.01); A61K 31/7056 (2013.01); A61K 38/28 (2013.01); A61K 47/22 (2013.01); A61P 3/00 (2018.01); A61P 3/04 (2018.01); A61P 3/06 (2018.01); A61P 3/10 (2018.01); A61P 5/50 (2018.01); A61P 9/12 (2018.01); A61P 29/00 (2018.01); A61P 31/12 (2018.01); C07D 309/10 (2013.01); C07D 333/12 (2013.01); C07D 333/56 (2013.01); C07D 335/02 (2013.01); C07D 493/08 (2013.01); C07D 493/10 (2013.01); C07H 5/10 (2013.01); C07H 7/04 (2013.01); C07H 15/203 (2013.01); C07H 17/00 (2013.01); C07H 17/02 (2013.01);
Abstract

The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a feline animal, preferably wherein the metabolic disorder is one or more selected from the group consisting of: ketoacidosis, pre-diabetes, diabetes mellitus type 1 or type 2, insulin resistance, obesity, hyperglycemia, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, atherosclerosis, inflammation of the pancreas, neuropathy and/or Syndrome X (metabolic syndrome) and/or loss of pancreatic beta cell function and/or wherein the remission of the metabolic disorder, preferably diabetic remission, is achieved and/or maintained.

Find Patent Forward Citations

Loading…